Robert T. Perri

789 total citations
22 papers, 647 citations indexed

About

Robert T. Perri is a scholar working on Molecular Biology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Robert T. Perri has authored 22 papers receiving a total of 647 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 8 papers in Genetics and 8 papers in Pathology and Forensic Medicine. Recurrent topics in Robert T. Perri's work include Lymphoma Diagnosis and Treatment (8 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Immunodeficiency and Autoimmune Disorders (4 papers). Robert T. Perri is often cited by papers focused on Lymphoma Diagnosis and Treatment (8 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Immunodeficiency and Autoimmune Disorders (4 papers). Robert T. Perri collaborates with scholars based in United States. Robert T. Perri's co-authors include Neil E. Kay, Martin M. Oken, John R. Hoidal, Richard B. Fox, John E. Repine, John I. Allen, Craig J. McClain, Robert P. Hebbel, Mark R. Wick and W Jaszcz and has published in prestigious journals such as Journal of Clinical Oncology, The American Journal of Medicine and European Journal of Immunology.

In The Last Decade

Robert T. Perri

21 papers receiving 608 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert T. Perri United States 11 168 149 143 142 132 22 647
J. Manaster Israel 14 175 1.0× 131 0.9× 125 0.9× 117 0.8× 23 0.2× 26 576
Daiki Abukawa Japan 18 49 0.3× 182 1.2× 120 0.8× 89 0.6× 54 0.4× 64 1.1k
Nanae Tsuruoka Japan 17 143 0.9× 218 1.5× 82 0.6× 162 1.1× 49 0.4× 76 908
Rania Baker United States 8 75 0.4× 246 1.7× 31 0.2× 47 0.3× 58 0.4× 8 823
Karen Simpson United States 10 497 3.0× 133 0.9× 192 1.3× 19 0.1× 140 1.1× 13 906
E Lusvarghi Italy 14 87 0.5× 118 0.8× 49 0.3× 21 0.1× 37 0.3× 62 647
G. R. Lee United States 6 249 1.5× 84 0.6× 19 0.1× 41 0.3× 116 0.9× 8 469
J Elmgreen Denmark 18 49 0.3× 108 0.7× 240 1.7× 88 0.6× 50 0.4× 45 717
Nikita Joshi United States 16 70 0.4× 210 1.4× 179 1.3× 68 0.5× 15 0.1× 29 809
Akihiko Ohno Japan 18 35 0.2× 216 1.4× 65 0.5× 96 0.7× 56 0.4× 41 963

Countries citing papers authored by Robert T. Perri

Since Specialization
Citations

This map shows the geographic impact of Robert T. Perri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert T. Perri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert T. Perri more than expected).

Fields of papers citing papers by Robert T. Perri

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert T. Perri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert T. Perri. The network helps show where Robert T. Perri may publish in the future.

Co-authorship network of co-authors of Robert T. Perri

This figure shows the co-authorship network connecting the top 25 collaborators of Robert T. Perri. A scholar is included among the top collaborators of Robert T. Perri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert T. Perri. Robert T. Perri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Luikart, Sharon D., Angela Panoskaltsis‐Mortari, Robert T. Perri, et al.. (2009). Mactinin, a fragment of cytoskeletal α-actinin, is a novel inducer of heat shock protein (Hsp)-90 mediated monocyte activation. BMC Cell Biology. 10(1). 60–60. 7 indexed citations
2.
Lichtman, Stuart M., Gina R. Petroni, Richard L. Schilsky, et al.. (2001). High Dose Cyclophosphamide Plus Recombinant Human Granulocyte-colony Stimulating Factor (rhG-CSF) in the Treatment of Follicular, Low Grade Non-Hodgkin's Lymphoma: CALGB 9150. Leukemia & lymphoma. 42(6). 1255–1264.
3.
Lichtman, Stuart M., Gina R. Petroni, Richard L. Schilsky, et al.. (2001). High Dose Cyclophosphamide Plus Recombinant Human Granulocyte-colony Stimulating Factor (rhG-CSF) in the Treatment of Follicular, Low Grade Non-Hodgkin's Lymphoma: CALGB 9150. Leukemia & lymphoma. 42(6). 1255–1264. 2 indexed citations
4.
Gilcrease, Michael Z., et al.. (1998). Fine Needle Aspiration of Signet-Ring Cell Lymphoma. Acta Cytologica. 42(6). 1461–1467. 8 indexed citations
5.
Omura, George, Robert T. Perri, Bercedis L. Peterson, & Charles A. Schiffer. (1994). Carboplatin in Previously Treated Multiple Myeloma. American Journal of Clinical Oncology. 17(3). 196–198. 1 indexed citations
6.
Niehans, G A, W Jaszcz, Robert T. Perri, et al.. (1992). Immunohistochemical identification of P-glycoprotein in previously untreated, diffuse large cell and immunoblastic lymphomas.. PubMed. 52(13). 3768–75. 73 indexed citations
7.
Perri, Robert T. & Neil E. Kay. (1989). Large granular lymphocytes from B‐chronic lymphocytic leukemia patients inhibit normal B cell proliferation. American Journal of Hematology. 31(3). 166–172. 6 indexed citations
8.
Kay, Neil E. & Robert T. Perri. (1988). Immunobiology of Malignant B Cells and Immunoregulatory Cells in B-Chronic Lymphocytic Leukemia. Clinics in Laboratory Medicine. 8(1). 163–177. 12 indexed citations
9.
Weisdorf, Daniel J., et al.. (1987). In vitro correlates of low dose Ara‐C efficacy: Clinical, cytogenetic, and bone marrow culture analysis. American Journal of Hematology. 25(1). 43–53. 6 indexed citations
10.
Perri, Robert T., Barry S. Wilson, & Neil E. Kay. (1986). Inhibition of B cell growth factor (BCGF) by monoclonal antibodies directed against the C3d receptor (CR2). European Journal of Immunology. 16(4). 350–355. 9 indexed citations
11.
Perri, Robert T. & Neil E. Kay. (1986). Abnormal T cell function in early‐stage chronic lymphocytic leukemia (CLL) patients. American Journal of Hematology. 22(1). 55–61. 19 indexed citations
12.
Perri, Robert T., et al.. (1985). Low‐dose ARA‐C fails to enhance differentiation of leukaemic cells. British Journal of Haematology. 59(4). 697–701. 17 indexed citations
13.
Perri, Robert T., John I. Allen, Martin M. Oken, Catherine Limas, & Neil E. Kay. (1985). Simultaneous presentation of relapsing Hodgkin's disease and treatment‐related non‐Hodgkin's lymphoma. Medical and Pediatric Oncology. 13(3). 122–125. 1 indexed citations
14.
Sylvester, Robert, et al.. (1984). Impaired Phenytoin Bioavailability Secondary to Cisplatinum, Vinblastine, and Bleomycin. Therapeutic Drug Monitoring. 6(3). 302–305. 17 indexed citations
15.
Allen, John I., Robert T. Perri, Craig J. McClain, & Neil E. Kay. (1983). Alterations in human natural killer cell activity and monocyte cytotoxicity induced by zinc deficiency.. PubMed. 102(4). 577–89. 125 indexed citations
16.
Kay, Neil E., Martin M. Oken, & Robert T. Perri. (1983). The influential T cell in B-cell neoplasms.. Journal of Clinical Oncology. 1(12). 810–816. 20 indexed citations
17.
Perri, Robert T., et al.. (1982). Zinc - In vitro and in vivo demonstration of its role in modulating human lymphocyte and monocyte tumor cell interaction. 30(2). 2 indexed citations
18.
Allen, John I., et al.. (1982). Scurvy: Bilateral lower extremity ecchymoses and paraparesis. Annals of Emergency Medicine. 11(8). 446–448. 7 indexed citations
19.
Hoidal, John R., et al.. (1981). Altered oxidative metabolic responses in vitro of alveolar macrophages from asymptomatic cigarette smokers.. PubMed. 123(1). 85–9. 178 indexed citations
20.
Perri, Robert T., Robert P. Hebbel, & Martin M. Oken. (1981). Influence of treatment and response status on infection risk in multiple myeloma. The American Journal of Medicine. 71(6). 935–940. 97 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J. Manaster Breakdown of academic impact, for papers by Daiki Abukawa Breakdown of academic impact, for papers by Nanae Tsuruoka Breakdown of academic impact, for papers by Rania Baker Breakdown of academic impact, for papers by Karen Simpson Breakdown of academic impact, for papers by E Lusvarghi Breakdown of academic impact, for papers by G. R. Lee Breakdown of academic impact, for papers by J Elmgreen Breakdown of academic impact, for papers by Nikita Joshi Breakdown of academic impact, for papers by Akihiko Ohno
Rankless by CCL
2026